Corporate, Science
Triple Hair Group consolidates its position as industry leader and innovator for its Therapy-07 prescription drug in the U.S.
  • The Company strengthens the protection of its intellectual property in the world’s largest market
  • The additional protection will reduce the risk of infringement of its flagship product, thereby increasing the value of its patent portfolio 


Triple Hair Group Inc. (“Triple Hair” or the “Company”), a global leader in the development of innovative treatments for alopecia, is pleased to announce that the United States Patent and Trademark Office has granted allowance for another composition-of-matter patent application which broadens and enhances the protection of Triple Hair’s flagship prescription product Therapy-07 for the United States.


“This is a major milestone for Triple Hair, as our additional patent will provide increased protection for our Therapy-07 intellectual property in the United States, the largest consumer market in the world,” said Jean-Philippe Gravel, President and CEO of Triple Hair. “It will notably provide our distribution partners with the means to deter competitors from copying our proven, tested formula, and could be very beneficial for Triple Hair over the long run as we aim to sign new partnerships and develop our market south of the border.”


Alopecia is an underserved global market, valued at US $7.8 billion in 2021 and estimated to reach US $14.2 billion by 2028.


Triple Hair has made it a strategic priority to continue to grow its intellectual property portfolio in Canada, the United States and globally in its key commercial markets. Triple Hair will continue its vigilance of the industry in order to protect its prescription product Therapy-07, as well as its significant investments in research and development and its patent and trademark portfolios globally.




About Triple Hair

Triple Hair Group Inc. is a Canadian biotechnology company specializing in developing innovative treatments for men and women suffering from alopecia. Its mission is to provide the underserved market with clinically proven and efficient prescription and over-the-counter treatments for hair regrowth.


The Company also sells its drug-free patented products for preventing hair loss and regaining hair density in mild to moderate cases of alopecia under the brands RIZNTM ( for men, and Plenty NaturalTM( for women. RIZNTM and Plenty NaturalTM allow hair loss sufferers in their early stages to access effective and natural hair growth solutions without a prescription easily.


For more information, visit the Company’s website, at